Merck Stock Downgraded: What It Means for Investors

Merck & Co., Inc.'s (NYSE:MRK) stock has taken a hit after being downgraded by Royal Bank Of Canada from an 'outperform' rating to a 'sector perform' rating. The price objective for the stock is now set at $150.00, suggesting a potential downside of 1.45% from its current price.

This downgrade comes as part of a larger trend in analyst opinions on MRK, with several firms having weighed in recently. BMO Capital Markets boosted their target price on Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an 'outperform' rating, while Barclays raised their price objective on Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an 'overweight' rating.

However, not all analysts share this optimistic view. Weiss Ratings downgraded Merck & Co., Inc. from a 'hold (c)' rating to a 'hold (c-)' rating in a recent research note. Additionally, Cantor Fitzgerald restated a 'neutral' rating and set a $120.00 price objective on shares of Merck & Co., Inc.